Tags

Type your tag names separated by a space and hit enter

Progressive muscle relaxation therapy for atopic dermatitis: objective assessment of efficacy.
Acta Derm Venereol. 2012 Jan; 92(1):57-61.AD

Abstract

The aims of this study were to validate the efficacy of progressive muscle relaxation (PMR) in patients with atopic dermatitis and to evaluate the serological parameters that may serve as objective measures of the efficacy of PMR. A total of 25 patients with atopic dermatitis were randomly assigned to either a PMR group (n = 15) or a control group (n = 10). Serum levels of nerve growth, neuropeptide Y, and Th2 cytokines (IL-4, IL-5, and IL-13) were measured at baseline and after one month. At baseline, only anxiety was positively correlated with pruritus score (state anxiety: R = 0.496, p = 0.014; trait anxiety: R = 0.423, p = 0.04). Serum levels of neuropeptide Y were inversely related to the State-Trait Anxiety Inventory (STAI) (state anxiety: R = -0.475, p = 0.019; trait anxiety: R = -0.418, p = 0.042) and pruritus scores (R = -0.451, p = 0.035). After one month of PMR therapy, the degree of pruritus and loss of sleep was significantly decreased in the PMR group (p < 0.001), but not among controls. State anxiety scores showed significant improvement after treatment only in the PMR group (p = 0.005). There were no significant changes in the serological parameters in either group. Reductions in Eczema Area and Severity Index (EASI) scores were significant, but similar, in both groups. PMR may be a useful adjunctive modality for the management of atopic dermatitis through the reduction of anxiety. No change was found in biological parameters, but it was observed that neuropeptide Y may be related to high levels of anxiety in atopic dermatitis at baseline.

Authors+Show Affiliations

Department of Dermatology, Yonsei University College of Medicine, Seodaemoon-gu, Seoul, South Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21879233

Citation

Bae, Byung Gi, et al. "Progressive Muscle Relaxation Therapy for Atopic Dermatitis: Objective Assessment of Efficacy." Acta Dermato-venereologica, vol. 92, no. 1, 2012, pp. 57-61.
Bae BG, Oh SH, Park CO, et al. Progressive muscle relaxation therapy for atopic dermatitis: objective assessment of efficacy. Acta Derm Venereol. 2012;92(1):57-61.
Bae, B. G., Oh, S. H., Park, C. O., Noh, S., Noh, J. Y., Kim, K. R., & Lee, K. H. (2012). Progressive muscle relaxation therapy for atopic dermatitis: objective assessment of efficacy. Acta Dermato-venereologica, 92(1), 57-61. https://doi.org/10.2340/00015555-1189
Bae BG, et al. Progressive Muscle Relaxation Therapy for Atopic Dermatitis: Objective Assessment of Efficacy. Acta Derm Venereol. 2012;92(1):57-61. PubMed PMID: 21879233.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Progressive muscle relaxation therapy for atopic dermatitis: objective assessment of efficacy. AU - Bae,Byung Gi, AU - Oh,Sang Ho, AU - Park,Chang Ook, AU - Noh,Seongmin, AU - Noh,Ji Yeon, AU - Kim,Kyung Ran, AU - Lee,Kwang Hoon, PY - 2011/9/1/entrez PY - 2011/9/1/pubmed PY - 2012/5/5/medline SP - 57 EP - 61 JF - Acta dermato-venereologica JO - Acta Derm. Venereol. VL - 92 IS - 1 N2 - The aims of this study were to validate the efficacy of progressive muscle relaxation (PMR) in patients with atopic dermatitis and to evaluate the serological parameters that may serve as objective measures of the efficacy of PMR. A total of 25 patients with atopic dermatitis were randomly assigned to either a PMR group (n = 15) or a control group (n = 10). Serum levels of nerve growth, neuropeptide Y, and Th2 cytokines (IL-4, IL-5, and IL-13) were measured at baseline and after one month. At baseline, only anxiety was positively correlated with pruritus score (state anxiety: R = 0.496, p = 0.014; trait anxiety: R = 0.423, p = 0.04). Serum levels of neuropeptide Y were inversely related to the State-Trait Anxiety Inventory (STAI) (state anxiety: R = -0.475, p = 0.019; trait anxiety: R = -0.418, p = 0.042) and pruritus scores (R = -0.451, p = 0.035). After one month of PMR therapy, the degree of pruritus and loss of sleep was significantly decreased in the PMR group (p < 0.001), but not among controls. State anxiety scores showed significant improvement after treatment only in the PMR group (p = 0.005). There were no significant changes in the serological parameters in either group. Reductions in Eczema Area and Severity Index (EASI) scores were significant, but similar, in both groups. PMR may be a useful adjunctive modality for the management of atopic dermatitis through the reduction of anxiety. No change was found in biological parameters, but it was observed that neuropeptide Y may be related to high levels of anxiety in atopic dermatitis at baseline. SN - 1651-2057 UR - https://www.unboundmedicine.com/medline/citation/21879233/Progressive_muscle_relaxation_therapy_for_atopic_dermatitis:_objective_assessment_of_efficacy_ L2 - https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-1189 DB - PRIME DP - Unbound Medicine ER -